



**Sangamo BioSciences, Inc.**  
Point Richmond Tech Center  
501 Canal Blvd., Suite A100  
Richmond, CA 94804  
510-970-6000 • 510-236-8951(Fax)

---

## **SANGAMO BIOSCIENCES ANNOUNCES FIRST-QUARTER 2002 TELECONFERENCE**

**Richmond, California** – April 18th, 2002 – Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its first-quarter financial results on Thursday, April 25, 2002 after the market closes. The earnings release will be followed by a conference call at 2:00 p.m. PDT, which will be open to the public. During the conference call, the company will review the results and discuss other business matters.

The conference call dial-in numbers are 800-730-7991 for domestic callers and 706-634-7552 for international callers. For those unable to listen in at the designated time, a conference call replay will be available for 1 week following the conference call, from approximately 4:00 p.m. PDT on April 25, 2002 to midnight PDT on May 2, 2002. The conference call replay numbers for domestic and international callers are 800-642-1687 and 706-645-9291 respectively. The conference ID number for the replay is 3900788.

### **About Sangamo**

Sangamo is focused on the research and development of novel transcription factors for the regulation of gene expression. Sangamo's Universal Gene Recognition™ technology enables the engineering of transcription factors known as zinc finger DNA-binding proteins, or ZFPs. By engineering ZFPs so that they can recognize a specific gene, Sangamo has created ZFP transcription factors that can control gene expression, and consequently, cell function. The company intends to establish Universal Gene Recognition as a widely used technology for commercial applications in pharmaceutical discovery, human therapeutics, clinical diagnostics, agriculture and industrial biotechnology. Over twenty leading pharmaceutical and biotechnology companies have utilized ZFPs. In addition, Sangamo is developing novel ZFP-based therapeutics for the treatment of cardiovascular disease. For more information about Sangamo, visit the company's web site at [www.sangamo.com](http://www.sangamo.com).

*This press release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the safe harbors created by those sections. Actual results may differ materially from these forward-looking statements. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release. Further, Sangamo assumes no obligation to update any guidance given on its upcoming conference call.*

Contact: Elizabeth Wolffe  
510-970-6000, x271

###